Furthermore, weight loss and increased fatty acid oxidation during the administration of SGLT2 inhibitors could contribute to the reduction of hepatic fat accumulation in patients with T2DM and NAFLD [113]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.